The Chemical Profile of Senna velutina Leaves and Their Antioxidant and Cytotoxic Effects by Campos, Jaqueline Ferreira et al.
Research Article
The Chemical Profile of Senna velutina Leaves and
Their Antioxidant and Cytotoxic Effects
Jaqueline Ferreira Campos,1 David Tsuyoshi Hiramatsu de Castro,1 Marcio José Damião,1
Heron F. Vieira Torquato,2 Edgar J. Paredes-Gamero,2,3 Carlos Alexandre Carollo,4
Leticia M. Estevinho,5 Kely de Picoli Souza,1 and Edson Lucas dos Santos1
1School of Environmental and Biological Science, Federal University of Grande Dourados, Rodovia Dourados Itahum, Km 12,
79.804-970 Dourados, MS, Brazil
2Department of Biochemistry, Federal University of Sa˜o Paulo, Rua Pedro de Toledo 669, 04039-032 Sa˜o Paulo, SP, Brazil
3Interdisciplinary Center of Biochemistry Investigation, University of Mogi das Cruzes, Av. Dr. Caˆndido Xavier de Almeida Souza,
No. 200, Mogi das Cruzes, SP, Brazil
4Center of Biological and Health Sciences, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
5Department of Biology and Biotechnology, Agricultural College of Braganc¸a, Polytechnic Institute of Braganc¸a,
Campus Santa Apolo´nia, 5301-855 Braganc¸a, Portugal
Correspondence should be addressed to Edson Lucas dos Santos; edson.lucas@pq.cnpq.br
Received 4 June 2016; Accepted 14 September 2016
Academic Editor: Jerzy Kruk
Copyright © 2016 Jaqueline Ferreira Campos et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Natural products can be a source of biomolecules with antioxidant activity which are able to prevent oxidative stress-induced
diseases and show antitumor activity, making them important sources of new anticancer drug prototypes. In this context, this
study aimed to analyze the chemical composition of an ethanol extract of Senna velutina leaves and to assess its antioxidant and
cytotoxic activities in leukemic cells. The antioxidant properties were evaluated using a DPPH free radical scavenging assay and
by examining the extract’s inhibition of AAPH-induced lipid peroxidation in human erythrocytes. Its cytotoxicity and possible
mechanisms of action were assessed in Jurkat and K562 leukemic cell lines. The ethanol extract contained flavonoids, such as
epigallocatechin, epicatechin, kaempferol heteroside, rutin, and dimeric and trimeric proanthocyanidin derivatives. The extract
exhibited antioxidant activity by scavenging free radicals and antihemolytic action, and it decreased malondialdehyde content in
human erythrocytes. Furthermore, the extract also induced leukemic cell death by activating intracellular calcium and caspase-
3, decreasing mitochondrial membrane potential, and arresting the cell cycle in S and G2 phases. Hence, S. velutina leaf extract
contains antioxidant and antileukemic biomolecules with potential applications in diseases associated with oxidative stress and in
the inhibition of tumor cell proliferation.
1. Introduction
Several diseases, including cancer, diabetes, atherosclerosis,
inflammatory diseases, and premature aging, are related to
oxidative stress [1]. Oxidative stress stems from excess of free
radicals in the body and low antioxidant activity, resulting
in damage to essential biomolecules such as nucleic acids,
proteins, and lipids [2].
Cancer is an oxidative stress-related disease that causes
high rates ofmorbidity andmortality in the global population
[3]. Leukemias are cancers that affect the cells of the hema-
topoietic system; depending on their cellular origin and
maturity stage, leukemias can be classified as either myeloid
or lymphoid and as acute or chronic [4]. Surgery, radio-
therapy, and chemotherapy [5] are among the main types of
treatment for these cancers.
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Biomolecules with anticancer activity at low therapeutic
doses and with reduced side effects have been increasingly
sought in recent decades [6]. Between 1940 and 2014, 49% of
the 174 anticancer drugs that weremade available on themar-
ket were either natural products or their derivatives [7].Thus,
there is a trend among the general population and themedical
community to regard medicinal plants as alternative sources
of antitumor drugs, provided that the therapeutic properties
of such plants have been scientifically researched and proven
[8]. The discoveries of paclitaxel [9], an anticancer drug, and
of homoharringtonine [10], which is used in the treatment of
acute and chronic myeloid leukemia, are examples of suc-
cessful cases in the development of medicinal plant-derived
drugs.
The search for newmoleculeswith therapeutic properties,
including antioxidant and anticarcinogenic activities, is facil-
itated by the vast biodiversity and bioprospecting potential in
Brazil. Senna genus has been used in Brazilian folk medicine
for its antioxidant, antimicrobial [11], anti-inflammatory [12],
antidiabetic [13], and antitumor [14] activities, among other
uses.
Taxonomically, some species have been transferred from
Cassia genus to Senna genus [15]. This taxon currently com-
prises 500–600 species [14, 16], of which many have not been
yet characterized with respect to their chemical compositions
and biological properties as the arboreal species Senna
velutina (Vogel) H. S. Irwin & Barneby (Fabaceae, Cae-
salpinioideae). In this context, the aim of the present study
was to determine the chemical composition of an ethanol
extract of S. velutina leaves and to evaluate its antioxidant and
antileukemic activities.
2. Materials and Methods
2.1. Plant Material and Extract Preparation. S. velutina leaves
were collected following the identification of the plant
and authorization of the SISBIO (Sistema de Autorizac¸a˜o
e Informac¸a˜o em Biodiversidade, permit number 54470-1)
in Dourados, Mato Grosso do Sul (S 22∘05󸀠545󸀠󸀠 and W
055∘20󸀠746󸀠󸀠), Brazil, oven-dried with the air circulation at a
temperature of 45±5∘C, and then ground in aWilly-type knife
mill. An exsiccated samplewas deposited in theHerbariumof
the Federal University of Grande Dourados, Mato Grosso do
Sul, Brazil, with registration number 4665.
The extract was then prepared by macerating the plant
material in an ethanol 95% mixture at room temperature in
the dark for 7 days. Then, the extract was filtered, and the
residue was further extracted twice using the same process.
After 21 days, the filtrate was concentrated in a rotary vacuum
evaporator (Gehaka, Sa˜o Paulo, SP, Brazil) to obtain the
ethanol extract of S. velutina leaves (ESV). The dry extract
yieldwas 29%, calculated using the following formula: extrac-
tion yield (%) = (weight of the freeze-dried extract × 100)/
(weight of the original sample). The ESV was stored at −20∘C
protected from light.
2.2. Chemical Analysis. The extract was analyzed by Ultra
Fast Liquid Chromatography (UFLC) (Shimadzu) coupled
to Diode Array Detector (DAD) (240–800 nm, Shimadzu)
and electrospray ionization time-of-flight (ESI-QTOF-
micrOTOF QII) (operating in positive and negative mode,
120–1200Da, Bruker Daltonics). A C-18 column was used
(Kinetex, 2.6 𝜇m, 150 × 2.2mm, Phenomenex) protected
by a guard column of the same material. The mobile phase
was as follows: water (solvent A) and acetonitrile (solvent B)
both with 0.1% of formic acid in a gradient of 0–2min 3%
B, 2–25min 3–25% B, and 25–40min 25–80% B followed
by washing and reconditioning of the column (8 minutes).
The flow rate was 0.3mL/min and 1 𝜇L (1mg/mL) of extract
was injected. The other micrOTOF-QII parameters were as
follows: temperature, 200∘C;N
2
drying gas flow rate, 9 L/min;
Nebulizer, 4.0 bar; capillary voltage, −3500V (negative) and
+4500V (positive); and internal calibration with TFA-NA
injected at the end of the chromatographic analysis.The rutin
and epicatechin standardswere obtained fromSigma-Aldrich
with a purity of ≥95%.
2.3. Antioxidant Activity
2.3.1. DPPH Free Radical Scavenging Activity. The 2,2-
diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activ-
ity of ESV was evaluated as described in D. Gupta and R. K.
Gupta [17], withmodifications. In this assay, 0.2mL of ESV at
different concentrations (1–1000𝜇g/mL) was added to 1.8mL
ofDPPH solution (0.11mM) in 80% ethanol.Themixture was
incubated for 30 minutes at room temperature in the dark.
Absorbance at 517 nm was then measured spectrophotomet-
rically. Ascorbic acid and butylhydroxytoluene (BHT) were
used as reference antioxidants. As a control, 0.2mL of solvent
used to dilute the extract was added to 1.8mL of DPPH
solution (0.11mM) in 80% ethanol. Two independent experi-
mentswere performed in triplicate.Thepercentage inhibition
was calculated relative to the control using the following
equation:
inhibition of DPPH radical (%)
= (1 − Abssample
Abscontrol
) × 100. (1)
2.3.2. Inhibition of Lipid Peroxidation in Human Erythrocytes
(1) Preparation of Erythrocyte Suspension. After approval
by the Research Ethics Committee (Comiteˆ de E´tica em
Pesquisa, CEP) of the University Center of Grande Dourados
(UNIGRAN, Brazil (CEP process number: 123/12)), periph-
eral blood from healthy donors was collected into tubes con-
taining sodium citrate which were then centrifuged at 400×g
for 10min. The plasma and leukocyte layer were discarded,
and the erythrocytes were washed 3 times with 0.9% sodium
chloride solution (NaCl) and centrifuged. Finally, 10% ery-
throcyte suspension was prepared in 0.9% NaCl solution to
attain a 2.5% final concentration for further analysis.
(2) Hemolytic Activity and Inhibition of Oxidative Hemolysis.
The ability of ESV to protect against lipid peroxidation was
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evaluated using an antihemolytic assay in human erythro-
cytes that were incubated with the oxidant 2,2󸀠-azobis-
(2-amidinopropane) dihydrochloride (AAPH), a thermoin-
ducible initiator of lipid peroxidation, as described by Cam-
pos et al. [18]. To evaluate hemolytic activity and inhibition
of oxidative hemolysis, erythrocytes were preincubated with
either ESVor ascorbic acid (25–125𝜇g/mL) at 37∘C for 30min
before the addition of 0.5mL of either 0.9% NaCl or 50mM
AAPH (dissolved in 0.9% NaCl). In the assay, 1% ethanol was
used as a solvent control, while 0.9% NaCl was used as the
baseline hemolysis control. Total hemolysis was induced by
incubating erythrocytes with distilled water. Samples were
incubated at 37∘C with regular stirring. The extent of hemol-
ysis was determined at 60-minute intervals for an incubation
period of 5 h. Tubes were centrifuged at 700×g for 5 minutes;
0.2mL of the supernatant was collected and added to 1.8mL
of 0.9% NaCl for spectrophotometric reading at 540 nm.
The hemolysis percentage was calculated using the formula𝐴/𝐵 × 100, where 𝐴 is the sample absorbance and 𝐵 is the
absorbance of the total hemolysis sample.Three independent
experiments were performed in triplicate.
(3) Malondialdehyde (MDA)Measurements.The inhibition of
malondialdehyde (MDA) production, which is a byproduct
of lipid peroxidation, was evaluated according to the method
described by Campos et al. [18]. Erythrocytes were preincu-
bated at 37∘C for 30minwith either ESV or ascorbic acid (25–
125 𝜇g/mL) before the addition of 0.5mL of 50mM AAPH
solution. The mixtures were incubated at 37∘C with regular
stirring; 1% ethanol was used as a negative control.TheMDA
concentration was determined at 60-minute intervals for a
total of 5 h. To determine the MDA concentration, samples
were centrifuged at 700×g for 5min; 0.5mL of each super-
natant was collected and transferred to a tube containing
1mL of 10 nM thiobarbituric acid (TBA), dissolved in 75mM
monobasic potassium phosphate buffer at pH 2.5. The stan-
dard controls used were 500 𝜇L of a 20mM MDA solution
and 1mL of TBA. Samples were incubated at 96∘C for 45min
and allowed to cool before adding 4mLof n-butyl alcohol and
centrifuging at 1600×g for 5min. The resulting supernatant
was read at 532 nm in a spectrophotometer. Two independent
experiments were performed in triplicate. Sample MDA
levels were expressed in nM/mL, according to the following
formula:
MDA = Abssample × (20 × 220.32Absstandard ) . (2)
2.4. Cytotoxic Activity
2.4.1. Cell Culture. Leukemia human cell lines Jurkat and
K562 were cultivated in RPMI 1640 (Sigma-Aldrich, Ger-
many) culture medium, supplemented with 10% fetal bovine
serum, 100U/mL penicillin (Sigma-Aldrich, Germany), and
100 𝜇g/mL streptomycin (Sigma-Aldrich, Germany). Cells
were cultured in a humidified incubator containing 5% CO
2
at 37∘C.
2.4.2. Cytotoxicity and Cell Death Profile. Cytotoxic activity
and the cell death profile were evaluated according to the
method described by Paredes-Gamero et al. [19]. Leukemic
cells were seeded at 105 cells/mL in 96-well microplates and
treated with ESV (0–100𝜇g/mL) for 24 h.Then, the cells were
centrifuged 600×g for 6min and resuspended in binding
buffer (0.14M NaCl, 2.5mM CaCl
2
, 0.01M HEPES, and pH
7.4) and incubated at room temperature with 1 𝜇L of Annexin
V-FITC (BD Biosciences, San Diego, CA, USA) and 5 𝜇g/mL
propidium iodide (PI) Becton Dickinson, USA for 20min.
Sample analysis was performed usingAccuri C6 flow cytome-
ter (Becton Dickinson, San Diego, CA, USA), with acquisi-
tion of 3,000 events.
2.4.3. Measurement of Mitochondrial Membrane Potential.
To evaluate the possible effects of ESV on mitochondrial
membrane potential, leukemic cells were incubated with
the fluorescent marker JC-1 (5,5󸀠,6,6󸀠-tetrachloro-1,1󸀠,3,3󸀠-
tetraethylbenzimidazolylcarbocyanine iodide; Molecular
Probes, Eugene, OR, USA) according to the method
described by Moraes et al. [20]. JC-1 probe accumulates in
mitochondria in a potential-dependent manner. Viable cells
with highmitochondrial membrane potential are stained red.
Upon reduction of the mitochondrial membrane potential,
cells appear green. In this assay, cells were seeded into
24-well plates (105 cells/mL) containing supplemented media
and were then incubated with 27.6𝜇g/mL (Jurkat cells) or
67.5 𝜇g/mL (K562 cells) ESV for 24 h. The cells were then
centrifuged and incubated with JC-1 (1 𝜇g/mL) for 15min at
room temperature. Fluorescence readings were performed
in a FACSCalibur flow cytometer using CellQuest software
(Becton Dickinson, San Diego, CA, USA). A total of 10,000
events were collected per sample.
2.4.4. Caspase-3 Activity. Caspase-3 activity was assessed
according to the method described by Moraes et al. [20],
with minor modifications. Caspase activity was measured by
flow cytometer. Leukemic lineages were treated with ESV
(27.6𝜇g/mL) in 24-well microplates (105 cells/mL) for 24 h.
Then the cells were fixed with 2% paraformaldehyde in PBS
for 30min and permeabilized with 0.01% saponin for 15min
at room temperature. Next, the cells were incubated for 1 h
at 37∘C with anti-cleaved-caspase 3-FITC antibody (Becton
Dickinson, USA). After incubation for 40min, the fluores-
cence was analyzed by Accuri C6 flow cytometer (Becton
Dickinson, USA). A total of 10,000 events were acquired.
2.4.5. Intracellular Calcium and Pan-Caspase Inhibitors. The
roles of intracellular calcium and caspases in ESV-promoted
cytotoxicity were evaluated according to Bechara et al. [21],
with minor modifications. Jurkat cells were pretreated for
1 h at 37∘C under a 5% CO
2
atmosphere with either the
intracelullar calcium chelator BAPTA-AMor the pan-caspase
inhibitor Z-VAD-FMK; ESV (27.6𝜇g/mL) was then added to
the cells and allowed to incubate for 24 h. Control and treated
cells were resuspended in culture medium containing 0.05%
trypan blue and were counted in a hemocytometer chamber
to determine cell viability (trypan blue exclusion assay).
2.4.6. Cell Cycle Phases. Distribution of cell cycle was deter-
mined by PI staining and flow cytometry analysis. Leukemic
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lineages (105 cells/mL) were treated with ESV (27.6𝜇g/mL)
for 24 h and then were fixed and permeabilized as previously
described and treated with 4mg/mL RNase (Sigma-Aldrich,
Germany) for 45min at 37∘C. For DNA labeling, cells were
incubatedwith 5𝜇g/mLof PI (SigmaAldrich,Germany). Per-
centages of cells within cell cycle compartments (G1, S, and
G2/M) were determined by Accuri C6 flow cytometer (Bec-
ton Dickinson, USA). A total of 10,000 events were acquired.
2.5. Statistical Analyses. The data are shown as the mean ±
standard error of the mean (SEM) and were analyzed for
statistical significant differences between the groups using
Student’s t-test for comparison between two groups and one-
way analysis of variance (ANOVA) followed by Dunnett’s
test for comparison of more than two groups using Prism 5
GraphPad Software. The results were considered significant
when 𝑃 < 0.05.
3. Results
3.1. Chemical Composition of ESV. The metabolites in ESV
were identified by interpreting the UV absorption and mass
spectra and comparing them with data in the literature.
When available, compounds were compared with authentic
standards for confirmation.
The identification of compound 2, withm/z 305.0660 [M-
H]−, was based on the fragmentation pattern of epigallo-
catechin proposed by Dou et al. [22], namely, m/z 261 [M-
CO
2
]−, m/z 219 [M-C
4
H
6
O
2
]−, m/z 179 [M-C
6
H
6
O
3
]−, m/z
167 [M-C
7
H
6
O
3
]−, and m/z 165 [M-C
7
H
8
O
3
]−, and also on
the detection of UV absorption at 270 nm.
Compounds 4, 8, and 9 showed UV absorption patterns
that were characteristic of flavonols (270 and 340 nm). Their
fragmentation patterns were consistent with those of hetero-
side derivatives of kaempferol, whose main fragment consists
ofm/z 285 [C
15
H
9
O
6
]−. Several compounds of this class have
been described in Senna genus [23, 24].
Dimeric (compounds 6, 7, and 10–14) and trimeric (com-
pounds 15–22) proanthocyanidins, comprising cassiaflavan,
afzelechin, epicatechin, epigallocatechin, and naringenin
subunits, were also observed.These derivatives, although rare
in nature, are often reported in Senna genus; some authors
consider them to be chemical markers for the genus [25–27].
The UV absorption maxima at 280 nm and the increase in
reverse-phase retention time concomitant with decreased
hydroxyl group content or increased degree of polymeriza-
tion are in agreement with the study by Callemien and Collin
[28]. Fragmentation patterns obtained by retro-Diels-Alder
(RDA) fission, heterocyclic ring fission (HRF), and quinone
methide (QM) can be used to characterize the subunits that
make up proanthocyanidins [29]. A complete discussion on
the elucidation of this class of compounds may be found
in the literature [29, 30]. Thus, based on retention times,
fragmentation profiles, and comparisons with previously
published data, 22 compounds in ESV were characterized
(Figure 1 and Table 1).
3.2. DPPH Free Radical Scavenging Activity. ESV was able to
scavenge the DPPH free radical, with a 2.5-fold higher IC
50
and maximum activity values relative to ascorbic acid; how-
ever, these values were lower than those obtained with BHT
(Table 2).
3.3. Hemolytic Activity and Inhibition of Oxidative Hemolysis.
Over the range of tested concentrations, ESV showed no
hemolytic activity in human erythrocytes, as no hemolysis
was observed after up to 5 h of incubation (Figure 2(a)).
The control antioxidant, ascorbic acid, was able to protect
erythrocytes from hemolysis for up to 4 h of incubation when
they were exposed to the oxidant AAPH (data not shown).
ESV was able to protect erythrocytes for 5 h over the tested
50–125𝜇g/mL concentration range (Figure 2(b)), demon-
strating its powerful antihemolytic activity.
3.4. MDAMeasurements. Thedegree of protection conferred
by ESV against AAPH-induced lipid peroxidation in human
erythrocytes was evaluated by measuring MDA levels. At
ESV concentrations of 100 and 125 𝜇g/mL, the MDA levels
were decreased throughout the course of the assay (data not
shown) and after 5 h of incubation (Figure 2(c)).
3.5. Cytotoxic Activity and Cell Death Profile. ESV promoted
cell death in both tested cell lines. IC
50
values indicated
that ESV was more effective in Jurkat cells than in the ery-
throleukemic cell line K562 (IC
50
= 27.6𝜇g/mL and 67.5𝜇g/
mL, resp.) (Figures 3(a) and 3(b)). ESV treatment promoted
double staining in both cell lines. This type of death was
evident in 71.9 ± 5.7% of Jurkat cells and 30.1 ± 2.8% of
K562 cells after treatment with 40 and 80𝜇g/mL of extract,
respectively (Figures 4(a) and 4(b)).
3.6. Mitochondrial Membrane Potential. The mitochondrial
membrane potentials of Jurkat and K562 leukemic cells
decreased after 24 h of incubation with ESV, as evidenced
by a decrease in red fluorescence and an increase in green
fluorescence compared to untreated cells. The mitochondrial
membrane potential was reduced by 91.0±4.3% in Jurkat cells
and by 74.7± 7.3% in K562 cells after treatment with 27.6 and
67.5 𝜇g/mL of extract, respectively (Figures 5(a) and 5(b)).
3.7. Caspase-3 Activity. The Jurkat cell line, which was more
sensitive to ESV activity, was used to investigate ESV-pro-
moted cell death mechanisms. The fluorescence histogram
(Figure 6(a)) showed a rightward shift (greater fluorescence
values), indicating the activation of the apoptosis-inducing
enzyme caspase-3. Cleaved caspase-3 levels increased 4.5-fold
in ESV-treated cells relative to untreated cells (Figure 6(b)).
3.8. Pan-Caspase Inhibition and Intracellular Calcium Chela-
tion. Jurkat cells were preincubated with the pan-caspase
inhibitor Z-VAD-FMK to assess whether ESV cytotoxicity
was mainly mediated by caspase activation. Z-VAD-FMK
pretreatment did not decrease ESV-induced cell death (Fig-
ure 7). However, the intracellular Ca2+ chelator BAPTA-AM
partially inhibited ESV-induced death in Jurkat cells (Fig-
ure 7).
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Figure 1: UFLC-DAD-ESI-QTOF-micrOTOFQII chemical profiling (negativemode) of an ethanol extract of S. velutina leaves. (a) Base peak
chromatograms (BPC). (b) Extract ion chromatogram (EIC) of m/z 305. (c) EIC of m/z 289. (d) EIC of m/z 593. (e) EIC of m/z 609. (f) EIC
ofm/z 545. (g) EIC ofm/z 529. (h) EIC ofm/z 513. (i) EIC ofm/z 785. (j) EIC ofm/z 769.
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Figure 2: Hemolysis and MDA content in human erythrocytes incubated for 5 hours with ascorbic acid (AA) and ESV (50–125 𝜇g/mL).
(a) Hemolytic activity of ESV in the absence of AAPH. (b) Antihemolytic activity after addition of AAPH. (c) Malondialdehyde (MDA)
concentration (nM/mL) after addition of the oxidizing agent. ∗𝑃 < 0.05 compared to the AAPH-only control (erythrocytes incubated with
oxidant only).
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Figure 3: Viability of leukemic Jurkat (a) and K562 (b) cells after treatment with different concentrations of ESV. ∗𝑃 < 0.05 compared to the
untreated control group.
3.9. Cell Cycle Phases. Histograms were used to show the
distributions of cell cycle phases in control and ESV-treated
Jurkat cells after 24 h of incubation (Figure 8(a)). The results
show a decreased portion of cells inG0/G1 phase (17.4±0.6%)
and increased portions of cells in S and G2/M phases (30.7 ±1.8% and 26.5 ± 1.9%, resp.) (Figure 8(b)). These results
indicate that ESV inhibits the progression of cell cycle
transitions.
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Figure 4: Cell death profiles of ESV-treated Jurkat (a) and K562 (b) cells. Anx−/PI−, viable cells; Anx+/PI−, apoptotic cells; Anx−/PI+, necrotic
cells; and Anx+/PI+, late apoptotic cells. ∗𝑃 < 0.05 compared to the respective control groups.
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Figure 5: Mitochondrial membrane potential of leukemic Jurkat (a) and K562 (b) cells treated with different ESV concentrations. ∗∗∗𝑃 <0.0001 compared to the untreated control group.
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Figure 6: Histogram (a) and representative graph (b) of caspase-3 activation in ESV-treated Jurkat cells. ∗∗∗𝑃 < 0.0001 compared to the
untreated control group.
Table 2: IC
50
and maximal DPPH radical scavenging activity of
standard antioxidants and of ESV.
Sample IC
50
(𝜇g/mL) Maximal inhibition
% 𝜇g/mL
Ascorbic acid 2.6 ± 0.8 90.9 ± 1.6 10
BHT 21.3 ± 1.2 92.4 ± 1.2 250
ESV 6.3 ± 1.3 92.4 ± 0.4 25
Values are means ± SEM.
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Figure 7: Involvement of caspases (via the pan-caspase inhibitor Z-
VAD-FMK) and intracellular calcium (using the chelator BAPTA-
AM) in ESV-induced Jurkat cell cytotoxicity. ∗𝑃 < 0.05 compared to
the untreated control group. #𝑃 < 0.05 compared to the ESV group.
4. Discussion
Brazilian biodiversity is rich in active compounds with high
potential for development of new therapeutic drugs, particu-
larly antioxidants and anticancer agents. Several plant species
found in Brazil have been characterized for their antioxidant
and cytotoxic activities in several tumor cell lines [31–33].
In the present study, an ethanol extract of S. velutina
leaves exhibited antioxidant activity and showed cytotoxic
effects against two leukemic cell lines, Jurkat and K562. The
antioxidant activity of ESV was demonstrated in AAPH-
incubated human erythrocytes; DPPH free radical scaveng-
ing and inhibition of lipid peroxidation led to decreases in
oxidative hemolysis and malondialdehyde production. This
activity of ESV is likely related to the presence of flavone
derivatives with antioxidant activity, such as epigallocatechin,
epicatechin, rutin, kaempferol glycosides, and dimeric and
trimeric proanthocyanidins, in the leaves [34–37].
Flavonoids can donate hydrogen atoms to radicals, pro-
tecting against lipid peroxidation, and this ability is associated
with the presence of a dihydroxylated B-ring [38]. Similar
to other phenolic compounds, the antioxidant activity of
flavonoids is ascribed to the presence of free hydroxyl groups
in themolecule, and the level of antioxidant activity increases
concomitantly with the number of hydroxyl groups [39].
Excess free radicals in the body can promote not only lipid
peroxidation but also oxidative DNA damage, leading to the
development of early stages of mutagenesis and carcinogen-
esis [40, 41]. Thus, compounds with antioxidant properties
have fundamental roles in preventing diseases such as cancer.
The cytotoxic activity of ESV against leukemic lines was
evaluated with an Annexin/PI-stain cell death assay. Further-
more, activation of caspase-3 was observed but was not con-
firmed to be a main mechanism of cell death when the pan-
caspase inhibitor Z-VAD-FMK was used. Different extracts
can promote several different death mechanisms simultane-
ously because of their different compositions. This fact com-
plicates the analysis and identification of specific cell death
pathways.
The ESV-induced decrease in mitochondrial membrane
potential is consistent with the observed cytotoxic effect of
ESV against leukemic cells.The changes in potential are likely
due to increased mitochondrial membrane permeability
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Figure 8: Histogram (a) and representative graph (b) of cell cycle distribution after 24 h of treatment with ESV. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001
compared to the untreated control group.
arising from an increase in intracellular calcium levels, a
characteristic of necrotic cell death [42, 43].
The present study demonstrated the involvement of
calcium in cell death, as the reduced cell viability of extract-
treated cells was reversed by incubation with the calcium
chelator BAPTA-AM. High calcium levels promote the open-
ing of mitochondrial permeability transition pores; these
pores are nonselective and thus release the contents of the
intermembrane space of the mitochondrion [44].
Another mechanism of the ESV-induced cytotoxicity
against Jurkat cells consists of cell cycle arrest. ESV promoted
a decrease in the number of cells in G0/G1 phase and an
increase in the number of cells in S andG2phases. Established
anticancer drugs, such as cisplatin and doxorubicin, exert a
similar profile change in the tumor cell cycle [14, 45]. Mueller
et al. [46] observed that cisplatin is likely to be active in G2/M
phases because cells in these phases are more sensitive to
DNAdamage, as DNA repairmechanisms are less active than
in G1/S phases. Flavonoids are phytochemicals that are
known to induce cell cycle arrest by decreasing cellular levels
of cyclin B and cyclin-dependent kinase 1, which are respon-
sible for controlling cell cycle progression between S and M
stages [47]. Furthermore, one of the major anticancer mech-
anisms ascribed to flavonoids is their ability to induce cell
cycle changes in tumor cell lines [48].Thus, cyclin-dependent
kinase inhibitors (CDKIs) have generated great interest for
their ability to arrest the tumor cell cycle and prevent tumor
cell proliferation; such cell cycle arrestmay be themainmech-
anism through which ESV operates [49]. However, plant
extracts are natural products with complex chemical compo-
sition, and biologically active compounds in extracts may act
alone or synergistically through different pathways.
In conclusion, an ethanol extract of S. velutina leaves
exhibited antioxidant activity and showed cytotoxic effects
Oxidative Medicine and Cellular Longevity 11
on leukemic cells by activating intracellular calcium and
caspase-3, decreasing mitochondrial membrane potential,
and arresting the cell cycle in S and G2 phases.
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